BIONET Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	154.48	81.32	5.37	-
Revenue Growth (YoY)	89.96%	1414.60%	-	-
Cost of Revenue	92.83	79.3	3.57	-
Gross Profit	61.65	2.02	1.8	-
Selling, General & Admin	115.89	54.14	6.31	0.67
Research & Development	62.2	47.24	34.75	11.86
Operating Expenses	178.1	101.38	41.06	12.53
Operating Income	-116.45	-99.36	-39.26	-12.53
Interest Expense	-0.08	-	-	-
Interest & Investment Income	18.03	11.82	1.89	0.02
Other Non Operating Income (Expenses)	1.07	1.29	0.03	-
Pretax Income	-97.43	-86.26	-37.34	-12.52
Net Income	-97.43	-86.26	-37.34	-12.52
Net Income to Common	-97.43	-86.26	-37.34	-12.52
Shares Outstanding (Basic)	70	57	15	1
Shares Outstanding (Diluted)	70	57	15	1
Shares Change (YoY)	22.04%	280.50%	1278.45%	-
EPS (Basic)	-1.39	-1.50	-2.47	-11.43
EPS (Diluted)	-1.39	-1.50	-2.47	-11.43
Free Cash Flow	-138.68	-154.96	-46.26	-3.47
Free Cash Flow Per Share	-1.98	-2.70	-3.06	-3.17
Gross Margin	39.91%	2.48%	33.49%	-
Operating Margin	-75.38%	-122.19%	-731.20%	-
Profit Margin	-63.07%	-106.07%	-695.44%	-
Free Cash Flow Margin	-89.77%	-190.56%	-861.52%	-
EBITDA	-104.68	-96.12	-38.68	-
EBITDA Margin	-67.76%	-118.21%	-	-
D&A For EBITDA	11.77	3.24	0.58	-
EBIT	-116.45	-99.36	-39.26	-12.53
EBIT Margin	-75.38%	-122.19%	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.